RegenxBio discloses second serious AE for hypercholesterolemia gene therapy

RegenxBio Inc. (NASDAQ:RGNX) said RGX-501 led to a second treatment-related serious adverse event in a Phase I/II trial to treat homozygous familial hypercholesterolemia (HoFH).

The open-label, international trial has enrolled six patients

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE